FDA Downgrades SMA Newborn Test to Class II
Published Date: 6/11/2026
Rule
Summary
The FDA is officially putting the Spinal Muscular Atrophy (SMA) newborn screening test into class II, meaning it has special safety rules but fewer hurdles than the strictest category. This change helps make the test safer and easier to get to babies who need it, starting June 11, 2026, with the classification effective since November 2022. Labs and device makers will benefit from clearer rules and faster access, helping catch SMA early without extra costs or delays.
Analyzed Economic Effects
5 provisions identified: 3 benefits, 2 costs, 0 mixed.
SMA Newborn Test Reclassified to Class II
The FDA classified the Spinal Muscular Atrophy (SMA) newborn screening test system as Class II (special controls), with the order effective June 11, 2026 and applicable since November 9, 2022. The agency says this classification provides reasonable assurance of safety and will enhance patients' access to the test.
Detailed Special-Control Study and Labeling Rules
To qualify under Class II, device makers must meet specified special controls, including extensive design verification and validation (detailed device description, analytical and clinical studies with summaries and 95% confidence intervals), multi-site reproducibility, lot-to-lot filter paper studies, reagent and shipping stability studies, software descriptions, and specific labeling statements (including that the test is prescription-only and presumptive positives require confirmatory diagnostic testing).
Lower Regulatory Hurdles for Test Makers
FDA says placing the SMA newborn screening test into Class II via the De Novo process reduces regulatory burdens and allows the device to serve as a predicate for future devices, which can speed market access for similar tests.
510(k) Premarket Submission Still Required
The order states that Spinal Muscular Atrophy newborn screening test systems are subject to premarket notification under section 510(k) of the FD&C Act at this time because FDA has not determined they should be exempt under section 510(m).
Prescription Screening; Positives Need Confirmation
The SMA newborn screening test system is identified as a prescription in vitro diagnostic intended to detect SMN1 gene deletions from dried blood spot specimens, and presumptive positive results are intended to be followed up by diagnostic confirmatory testing.
Your PRIA Score
Personalized for You
How does this regulation affect your finances?
Sign up for a PRIA Policy Scan to see your personalized alignment score for this federal register document and every other regulation we track. We analyze your financial profile against policy provisions to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
2026-11760 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Establishment, Maintenance, and Availability of Records; Additional Traceability Records for Certain Foods
The FDA is asking for approval to collect extra records from food businesses that handle certain high-risk foods. This helps track food sources quickly to keep everyone safe. Food companies should get ready to keep and share these new records, and comments on this plan are due by July 13, 2026.
2026-11762 — Agency Information Collection Activities; Submission for Office of Management and Budget Review; Comment Request; Procedures for the Safe Processing and Importing of Fish and Fishery Products
The FDA is asking for approval to keep collecting info from seafood processors and importers to make sure fish products are safe using a system called HACCP. This affects anyone who processes or imports fish and requires them to keep records showing they’re following safety rules. Comments on this plan are open until July 13, 2026, and there’s no new cost, just a continuation of current paperwork.
2026-11578 — Amending Over-the-Counter Monograph M020: Sunscreen Drug Products for Over-the-Counter Human Use, and Related Information
The FDA just gave a thumbs-up to adding bemotrizinol as a new active ingredient in sunscreens, letting it be used up to 6% concentration. This means sunscreen makers can now include this ingredient, which is safe and effective, in their products. The change is official as of June 10, 2026, and could lead to better sun protection options without extra costs for consumers.
2026-11589 — Medical Devices; Ear, Nose, and Throat Devices; Classification of the Combined Acoustic and Electrical External Stimulation Device for the Relief of Tinnitus
The FDA has officially placed the combined acoustic and electrical external stimulation device for tinnitus relief into class II, meaning it now has special safety rules but fewer regulatory hurdles. This change helps patients get access to this innovative device faster and ensures it’s safe and effective. The new classification is effective June 10, 2026, with the rules applying retroactively from March 6, 2023.
2026-11429 — Determination That Protamine Sulfate (Protamine Sulfate) Intravenous; Solution, 50 Milligrams/5 Milliliters, and Other Drug Products Were Not Withdrawn From Sale for Reasons of Safety or Effectiveness
The FDA has decided that Protamine Sulfate and some other drugs weren’t taken off the market because they’re unsafe or don’t work. This means generic drug makers can keep getting approval to sell their versions, as long as they follow the rules. Patients and pharmacies can keep counting on these medicines without any interruptions or extra costs.
Previous / Next Documents
Previous: 2026-11739 — Medical Devices; Immunology and Microbiology Devices; Classification of the Simple Point-of-Care Device to Directly Detect SARS-CoV-2 Viral Targets From Clinical Specimens in Near-Patient Settings
The FDA is officially putting simple COVID-19 rapid test devices into a safer, easier-to-manage category called Class II. This change means these tests can get to patients faster and with fewer hoops to jump through, while still making sure they work well and stay safe. Starting June 11, 2026, companies making these tests will follow new rules that help speed up innovation without extra costs.
Next: 2026-11747 — Safety Zones; Annual Events in the Captain of the Port Eastern Great Lakes Zone
The Coast Guard is setting up safety zones on the water for fun annual events in the Eastern Great Lakes this July 2026. Boat operators must follow rules and listen to Coast Guard directions during these times to keep everyone safe. These temporary zones might delay some boaters but won’t cost extra money.